CClinicalTrials.gg
Not yet recruitingNCT07655674Updated Jun 18, 2026

Endofaster Robot for Gastroesophageal Submucosal Tumors: A Randomized Controlled Study

An interventional study of Robot system and Non-robotic conventional endoscopy in Gastric Submucosal Tumors, sponsored by The First Affiliated Hospital of Soochow University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by The First Affiliated Hospital of Soochow University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

In endoscopic treatment for gastric submucosal tumors arising from the muscularis propria, does robot-assisted surgery yield a higher serosa preservation rate, shorter operative time and lower complication rates than conventional endoscopic procedures?

Read the detailed description

For endoscopic treatment of gastric submucosal tumors originating from the muscularis propria, this study aims to explore whether robot-assisted therapy can improve serosa preservation rate, shorten operative time and reduce complications compared with conventional endoscopic surgery.

02

Conditions studied

  • Gastric Submucosal Tumors

Keywords

  • gastric submucosal tumors
  • Robotic endoscope
03

In context

Lead sponsor

The First Affiliated Hospital of Soochow University is the lead sponsor of 252 studies on the registry; 148 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Aged 18 to 80 years old;
  2. Submucosal tumors originating from the muscularis propria of gastric fundus, highly suspected as gastrointestinal stromal tumor (GIST) confirmed by endoscopic ultrasonography (EUS) and contrast-enhanced computed tomography (CT);
  3. Tumor diameter ranging from 1.0 cm to 3.0 cm;
  4. No active ulcer or bleeding on the lesion surface before operation;
  5. American Society of Anesthesiologists (ASA) physical status class I-III;
  6. Voluntarily signed written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Tumor adhesion to serosa with unclear interface shown on EUS;
  2. High-risk GIST or distant metastasis indicated by imaging or endoscopy;
  3. History of gastric surgery or radiotherapy;
  4. High bleeding risk including coagulation disorders and patients unable to discontinue anticoagulant medications;
  5. Pregnant or breastfeeding women;
  6. Failure to cooperate with follow-up.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    RG(Robot group)

    1.Marking and mucosal incision.2.Grasp the tumor or its pedicle with the robotic flexible arm, apply continuous and steady traction toward the luminal side to dynamically expose the anatomical space between the tumor capsule and normal muscular layer.3.Perform meticulous dissection along the capsule-muscular layer interface using an ESD knife, and preserve the integrity of the serosa as much as possible.4.En bloc resection and removal of the tumor.5.Verification of serosal integrity: The procedure can be completed only if air/water insufflation test shows negative results. Mucosal defects are closed by standard techniques.

    Device: Robot system

  • Active comparator
    TG(Traditional Group)

    The procedures are performed by surgeons of equivalent seniority via conventional endoscopic full-thickness resection (EFTR) or modified endoscopic submucosal dissection (modified ESD). If a safe dissection plane cannot be established, full-thickness incision is conducted followed by closure using over-the-scope clip (OTSC), covered stent or suturing techniques. Leakage is assessed and managed in accordance with standard protocols.

    Device: Non-robotic conventional endoscopy

Interventions

  • DeviceRobot system

    After Marking and mucosal incision,Grasp the tumor or its pedicle with the robotic flexible arm, apply continuous and steady traction toward the luminal side to dynamically expose the anatomical space between the tumor capsule and normal muscular layer.

  • DeviceNon-robotic conventional endoscopy

    Conventional endoscopy without Robot

06

What researchers measure

Primary outcomes

  1. Serosa integrity rate

    En bloc resection rate with serosa preserved

    Time frame: perioperative

Secondary outcomes

  1. Duration of the surgical procedure

    Total duration of the surgical procedure

    Time frame: Intraoperative

  2. Dissection time

    Dissection time of tumor

    Time frame: perioperative

  3. Intraoperative blood loss

    Intraoperative blood loss during surgury

    Time frame: perioperative

  4. Postoperative fever rate

    Postoperative fever is defined as a body temperature ≥ 37.5 ℃ within 7 days after surgery. All febrile cases during this period are included, including non-infectious absorption fever.

    Time frame: Within 7 days after surgery

  5. Postoperative infection

    Postoperative infection is diagnosed when body temperature reaches ≥ 38.5 ℃, or temperature ≥ 38.0 ℃ persists for more than 3 consecutive days starting from postoperative day 3. Diagnosis shall be confirmed by clinical symptoms, abnormal laboratory inflammatory indicators or positive microbial culture results. Simple absorption fever is excluded.

    Time frame: Within 30 days after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — The shared datasets cover all collected de-identified individual participant data related to this trial, such as demographic data, imaging findings, surgical data, complication records and pathological results. No personal identifiable information will be retained. Data will be available to qualified researchers for legitimate scientific research use.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07655674
Lead sponsor
The First Affiliated Hospital of Soochow University
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jun 18, 2026

Study contacts

Chenhuan Tan
Contact
tanchenhuan2013@163.com
+86 18860928860
Rui Li
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion